Universe Pharmaceuticals INC — FY2022 Form 20-F Summary
Reporting period: Fiscal year ended September 30, 2022; this is an annual report, not a standalone 2022 fourth-quarter filing. Filed February 10, 2023. Financial figures below are in U.S. dollars unless stated otherwise.
Business context
Universe Pharmaceuticals is a Cayman Islands holding company whose operations are conducted through PRC subsidiaries. It manufactures traditional Chinese medicine derivative (TCMD) products and distributes medicines, medical instruments, and other products made by third parties. It reported 13 products manufactured in-house, sold across 30 provinces, alongside a portfolio of third-party products. Its signature product, Guben Yanling Pill, represented 42.5% of FY2022 revenue. The company reported 21.75 million ordinary shares outstanding at fiscal year-end.
Key financial metrics
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue | $40.14 million | $47.98 million |
| Gross profit / gross margin | $21.89 million / 54.5% | $25.33 million / 52.8% |
| Operating income (loss) | $(7.44) million | $13.59 million |
| Net income (loss) | $(8.74) million | $11.32 million |
| Net margin | (21.8)% | 23.6% |
| Operating cash flow | $(1.31) million | $(2.06) million |
| Cash at year-end | $5.71 million | $8.08 million |
FY2022 cost of revenue was $18.25 million. Selling expenses rose to $19.08 million, including $17.53 million of advertising expense; research and development expense increased to $7.64 million. The company reported a $0.40 diluted loss per share, compared with $0.60 diluted earnings per share in FY2021.
At September 30, 2022, current assets were $41.51 million, current liabilities $13.10 million, and reported working capital $28.4 million. Current assets included $13.15 million in redeemable-at-discretion wealth-management investments, $15.18 million in net receivables, and $2.21 million in inventory. Short-term bank loans were $3.94 million; an additional $3.38 million was due to related parties, non-interest-bearing and payable on demand. Total assets were $59.54 million and shareholders’ equity was $46.44 million.
Changes versus FY2021
- Revenue fell 16.3%. In-house TCMD sales declined 18.8% to $23.99 million; third-party product sales declined 12.3% to $16.15 million.
- TCMD unit sales volume dropped 37.2%, while average selling price rose 29.1% to $2.22 per unit. Management attributed lower shipments to COVID-related logistics and travel restrictions; raw-material prices increased about 5% year over year.
- Gross margin improved 1.7 percentage points to 54.5%, but gross profit fell 13.6% as lower sales outweighed margin improvement.
- Selling expense increased 541.8%, primarily due to advertising. Total operating expenses rose 149.9% to $29.33 million, turning operating income into an operating loss.
- Cash from operations remained negative. Cash declined by $2.37 million during the year; financing included $3.32 million of related-party borrowing. Short-term investment results shifted from $0.24 million of income to a $0.47 million loss.
Outlook, risks, and unusual items
- Outlook: The filing provides no quantified revenue or earnings guidance. Management said COVID-related uncertainty could cause revenue and cash flow to underperform over the following 12 months. It expects selling, general and administrative, and R&D costs to increase as the business expands.
- Expansion commitments: Construction of four manufacturing plants and an office building, budgeted at approximately RMB165 million, was delayed from the original 2023 target to an estimated December 2024 completion. Remaining capital expenditure was estimated at $13.47 million, including about $3.48 million within 12 months. The contractor was to bear increased material and labor costs.
- Acquisition and related-party transactions: The company prepaid approximately $3.51 million under a letter of intent to acquire 51% of Yunnan Faxi for RMB72 million; completion and remaining payment were expected in June 2023. It also had a $2.25 million prepayment toward property purchased under an agreement with an entity that was related to the CEO when the agreement was made; the company had not received occupancy certification or access to the property by the report date.
- Strategic cooperation: Agreements with Japan’s Kitanihon Pharmaceutical contemplated a new manufacturing and R&D facility funded by Universe and a $1.56 million investment in Kitanihon. As of the report date, construction had not begun and the shares had not been acquired.
- Controls and governance: Management concluded disclosure controls and internal control over financial reporting were ineffective at September 30, 2022, citing insufficient accounting personnel with U.S. GAAP and SEC reporting expertise. The material weakness had not been fully remediated. The financial statement auditor issued an unqualified opinion but did not attest to internal-control effectiveness.
- Other risks: PRC regulatory and cash-transfer restrictions, foreign-exchange exposure, supply and raw-material price volatility, competition, product liability, and the company’s dependence on a concentrated flagship product are significant risks. It lacked product-liability and business-interruption insurance. The filing also identifies potential liabilities for incomplete employee social-insurance and housing-fund contributions before April 2020.
- Listing: The company reported regaining Nasdaq’s $1 minimum bid-price compliance in November 2022, while warning that future listing deficiencies remained possible. It reported no material litigation and no material reportable subsequent events through the report date.
Important facts for investors to verify
- Whether post-year-end collections support the reported $15.18 million net receivable balance: the filing says about 71.9%, or $10.9 million, had been collected by the report date.
- Whether the exceptional advertising spend generated measurable sales or brand gains, and whether ongoing marketing costs remain elevated.
- Whether the Yunnan Faxi transaction and Kitanihon investment proceeded on the disclosed terms, and whether the related-party property was delivered and properly approved.
- Whether construction milestones, remaining capital needs, and funding plans for the delayed facilities remain achievable.
- Whether internal-control remediation has been completed and whether the company can sustain positive operating cash flow without further related-party advances or borrowing.
- Whether the $3.38 million demand-related-party balance, bank-loan renewals, PRC cash-transfer limits, and historical social-insurance exposure create additional liquidity or compliance risk.